Overview
- The randomized global trial failed to meet its primary endpoint of overall survival versus standard-of-care docetaxel.
- LATIFY enrolled 594 patients across more than 20 countries with locally advanced or metastatic NSCLC lacking actionable genomic alterations.
- AstraZeneca reported the combination was generally well tolerated with a safety profile consistent with each medicine and no new safety concerns.
- Key secondary endpoints included progression-free survival, objective response rate, duration of response, disease control rate and patient-reported outcomes.
- AstraZeneca said detailed results will be presented at a forthcoming medical meeting, and independent coverage has corroborated the topline outcome.